Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

#1308

Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.

Aim(s): To investigate the prognostic factors in Chinese patients with advanced pNETs and compare progression free survival (PFS) of patients treated with somatostatin analogues (Arm S), targeted therapy (Arm T) and chemotherapy (Arm C) in 1st line as well as in tumors with ki67 index <10% or >=10%.

Materials and methods: We retrospectively analyzed the data of 55 patients with progressive advanced well-differentiated pNETs receiving medical treatments at Peking Union Medical College Hospital from April 2009 to May 2015.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Cheng Y, Gao H, Bai C, Ying H, Meng C,

Keywords: Advanced pancreatic neuroendocrine tumors, systemic treatment, prognostic factor,